Results 1176 - 1200 of 1357

Financé par l’Agence des États-Unis pour le Développement international (USAID) et mis en œuvre par Management Sciences for Health et ses partenaires de mise en œuvre, le projet Integrated Health Services Activity (IHSA) au Bénin demande aux entreprises intéressées et qualifiées qui satisfont aux critères d'éligi

Essential medicines improve health and save lives. However, the complex system that is needed to get them to people does not always function well. Shortages of medical products are common. Poor quality and high costs burden patients and health ministries. Antimicrobial resistance, fed by inappropriate use, is spreading and may greatly undermine progress in global health.

For decades, the lead of the USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program consortium, Management Sciences for Health (MSH), has supported governments around the world in building resilient health systems that have the sustainable capability to take coordinated, measurable actions to prevent epidemics, detect biological threats early, and respond rapidly to disease out

The Community Health Planning and Costing Tool, a UNICEF tool developed by Management Sciences for Health, is designed to cost packages of community health services (CHS) and produce results to help assess performance, plan future services, and prepare investment cases. This handbook, which corresponds to the Community Health Planning and Costing Tool version 2.0, describes the process for co

Strengthening a country’s capacity to lead its own development is a cornerstone of the United States Government’s foreign assistance efforts. As a prerequisite to receiving direct funding assistance, donors, such as USAID, must assess an organization’s management and systems readiness for the responsible stewardship of funds.

Postpartum hemorrhage (PPH) remains one of the major causes of maternal mortality.

UNICEF, in partnership with Management Sciences for Health (MSH), is pleased to launch Version 2.0 of the Community Health Planning and Costing Tool.

Please download to read the USAID Safe, Affordable, and Effective Medicines for Ukrainians (SAFEMed) Activity in Ukraine News Digest, April 2020 edition. 

MSH, through an Innovation Fund grant of the Reproductive Health Supplies Coalition, and with contribution from the USAID-funded Uganda Health Supply Chain Program, supported Uganda to implement integration of oxytocin, the first-line medicine to prevent and treat excessive bleeding postpartum hemorrhage after delivery, into the vaccine cold chain for improved storage.

Elections usually involve large, nationwide gatherings, not only on Election Day but also, for example, during campaign rallies and voter registration drives. These events increase human-to-human contact and the risks of direct and indirect disease transmission.

The spread of COVID-19 has disrupted lives, communities, and economies worldwide.

To describe trends in diagnostic and treatment delays and estimate their effect on  rifampicin-resistant tuberculosis (RR-TB) mortality, we conducted a retrospective analysis of individual-level data including 748 (85.4%) of 876 patients diagnosed with RR-TB notified to the World Health Organization between 1 July 2005 and 31 December 2016 in Rwanda. Logistic regression was used to estimate the effect of diagnostic and therapeutic delays on RR-TB mortality. Between 2006 and 2016, the median diagnostic delay significantly decreased from 88 days to 1 day, and the therapeutic delay from 76 days to 3 days. Simultaneously, RR-TB mortality significantly decreased from 30.8% in 2006 to 6.9% in 2016.

ABSTRACTBackgroundSince the declaration of the 10th Ebola Virus Disease (EVD) outbreak in DRC on 1st Aug 2018, several neighboring countries have been developing and implementing preparedness efforts to prevent EVD cross-border transmission to enable timely detection, investigation, and response in the event of a confirmed EVD outbreak in the country.

BackgroundTuberculosis (TB) is a major public health problem. Its magnitude the required interventions are affected by changes in socioeconomic condition and urbanization. Ethiopia is among the thirty high burden countries with increasing effort to end TB.

This commentary highlights the challenges for pharmacovigilance (PV) posed by the COVID-19 pandemic and how PV practitioners in Africa can use this opportunity to strengthen patient safety. The commentary discusses remedies that lack clinical evidence and are potentially dangerous and the hidden effects of irrational use of medicines and medical products. It also examines the increase in poor reporting of adverse effects as well as the weakening of PV systems. It concludes that drug safety practitioners need to be vigilant about these risks and strengthen reporting systems to document, characterize, communicate, and minimize the risks of such remedies.

Please download to read the USAID Safe, Affordable, and Effective Medicines for Ukrainians (SAFEMed) Activity in Ukraine News Digest, May 2020 edition. 

Cote d’Ivoire health systems are being decentralized to prioritize decision making at the regional and departmental levels. Through strengthening leadership, management, and governance (LMG) skills of these decision makers, a stronger, self-sufficient system is created to be responsive to local needs.

Effective pharmacy services improve patient outcomes and satisfaction by ensuring that life-saving products are available and providing care that helps patients use products safely and appropriately.

PV is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other possible medicine-related problems. Adverse effects of medicines, particularly those that are unexpected, can negatively affect patients’ health and quality of life and further strain and undermine trust in the health care delivery system.

To determine the yield of tuberculosis (TB) and the prevalence of human immuno-deficiency virus (HIV) among key populations in the selected hotspot towns of Ethiopia, we undertook cross-sectional implementation research during August 2017-January 2018. A total of 1878 vulnerable people were screened. There was a statistically significant association of active TB cases with previous history of TB (Adjusted Odds Ratio (AOR): 11 95% CI, 4.06–29.81), HIV infection (AOR: 7.7 95% CI, 2.24–26.40), and being a health care worker (HCW). The prevalence of TB in key populations was nine times higher than 164/100,000 national estimated prevalence rate. The prevalence of HIV was five times higher than 1.15% of the national survey. The highest yield of TB was among HCWs and a high HIV burden was detected among female sex workers and internal migratory workers. These suggest the need for community and health facility based integrated and enhanced case finding approaches for TB and HIV in hotspot settings.

National HIV testing policies aim to increase the proportion of people living with HIV who know their status. National HIV testing policies were reviewed for each country from 2013 to 2018, and compared with WHO guidance. Three rounds of health facility surveys were conducted to assess facility level policy implementation in Karonga (Malawi), uMkhanyakude (South Africa), and Ifakara (Tanzania). A policy "implementation" score was developed and applied to each facility by site for each round. Most HIV testing policies were explicit and aligned with WHO recommendations. Policies about service coverage, access, and quality of care were implemented in >80% of facilities per site and per round. However, linkage to care and the provision of outreach HIV testing for key populations were poorly implemented. The proportion of facilities reporting HIV test kit stock-outs in the past year reduced over the study period in all sites, but still occurred in ≥17% of facilities per site by 2017. The implementation score improved over time in Karonga and Ifakara and declined slightly in uMkhanyakude. Efforts are needed to address HIV test kit stock-outs and to improve linkage to care among people testing positive in order to reach the 90-90-90 targets.

To assess the use of Xpert for accurate diagnosis, timely initiation, and rational use of anti-TB treatment among childhood TB patients, we reviewed data trends over four consecutive years; two years before the arrival of the machine and two years following the implementation of Xpert. During the intervention period (2016–2017), 371 children with presumptive TB were evaluated using Xpert. A total of 199 (53.6%) childhood TB cases were notified, of which 88 (44.2%) were Xpert positive and 111 (55.8%) were treated as Xpert-negative probable TB cases. The tendency to initiate anti-TB treatment for unconfirmed TB cases was reduced by a third. Compared with smear AFB, Xpert improved accuracy of diagnosing pediatric TB cases two-fold. The average waiting time to start anti-TB treatment was 1.33 days. There was a significant reduction in the waiting time to start anti-TB treatment, with a mean time difference before and during intervention of 5.62 days. Xpert use was associated with a significant increase in the accuracy of identifying confirmed TB cases, reduced unnecessary anti-TB prescription, and shortened the time taken to start TB treatment.

Accurate immunization delivery costs are necessary for assessing the cost-efectiveness and strategic planning needs of immunization programs. From a database of empirical immunization costing studies, we extracted estimates of the delivery cost per dose for routine childhood immunization services, excluding vaccine costs. We estimated the prediction model using the results from 29 individual studies, covering 24 countries. The predicted economic cost per dose for routine delivery of childhood vaccines (2018 US dollars), not including the price of the vaccine, was $1.87 (95% uncertainty interval $0.64–4.38) across all LMICs. By individual cost category, the programmatic economic cost per dose for routine delivery of childhood vaccines was $0.74 ($0.26–1.70) for labor, $0.26 ($0.08–0.67) for supply chain, $0.22 ($0.06–0.57) for capital, and $0.65 ($0.20–1.66) for other service delivery costs. The cost estimates from this analysis provide a broad indication of immunization delivery costs that may be useful when accurate local data are unavailable.

To investigate SARS-CoV-2 (the virus causing COVID-19) infection and exposure risks among grocery retail workers, and to investigate their mental health state during the pandemic, this cross-sectional study was conducted in May 2020 in a single grocery retail store in Massachusetts, USA. Among 104 workers tested, 21 (20%) had positive viral assays. Seventy-six percent of positive cases were asymptomatic. After multi-variate adjustments, employees with direct customer exposure had an odds of 4.7 (95% CI 1.2 to 32.0) being tested positive for SARS-CoV-2, while smokers had an odds of 0.1 (95% CI 0.01 to 0.8) having positive assay. As to mental health, the prevalence of anxiety and depression was 24% and 8%, respectively. Employees with direct costumer exposure were 5 times more likely to test positive for SARS-CoV-2.

Effective implementation of policies for expanding antiretroviral therapy (ART) requires a well-trained and adequately staffed workforce. Changes in national HIV workforce policies, health facility practices, and provider experiences were examined in rural Malawi and Tanzania between 2013 and 2017. In both countries, task-shifting and task-sharing policies were explicit by 2013. In facilities, the cadre mix of providers varied by site and changed over time, with a higher and growing proportion of lower cadre staff in the Malawi site. In Malawi, the introduction of lay counsellors was perceived to have eased the workload of other providers, but lay counsellors reported inadequate support. Both countries had guidance on the minimum numbers of personnel required to deliver HIV services. However, patient loads per provider increased in both settings for HIV tests and visits by ART patients and were not met with corresponding increases in provider capacity in either setting. Providers reported this as a challenge. Although increasing patient numbers bodes well for achieving universal antiretroviral therapy coverage, the quality of care may be undermined by increased workloads and insufficient provider training. Task-shifting strategies may help address workload concerns, but require careful monitoring, supervision and mentoring to ensure effective implementation.